Bristol-Myers Squibb Company (BMY) · page 98 of 197
The slide uses a table to systematically dismantle the credibility of management's revenue projections for the Celgene acquisition.
Activist deck · problem_statement · diagnose_problem · dense density
Slide locked Sign in to view
Slide schematic 6/6
diagram 1/1 paragraph 1/1 source-note 1/1 table 1/1 title 2/2
Components 6
other paragraph source-note data action-title headline
Tools 0
∅
No tools
No canon tool match is anchored to this slide.
Metrics 0
∅
No metrics
No metric insight is anchored to this slide.
Frameworks 1